Ifm_05-may 2022 Direct

If you are looking for guidance based on this study's results:

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. IFM_05-May 2022

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. If you are looking for guidance based on

Lenalidomide was the primary drug used for maintenance in this study. Key Findings: IFM_05-May 2022

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.